Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CPG 10101 Combination Therapy for the Treatment of Hepatitis C in Non-Responder (Null and Partial Responder) Hepatitis C Virus (HCV) Genotype I Infected Subjects


CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase II Randomized, Open Label, Multi-Center, Parallel Arm, Controlled Trial of CPG 10101 at Two Different Dose Levels With Pegylated-Interferon-Alpha 2B (PEG-IFN) Plus Ribavirin (RVN) or PEG-IFN Plus RVN Without CPG 10101 in the Treatment of Non-Responder (Null and Partial Responder) HCV Genotype 1 Infected Subjects




The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) compared to PEG-IFN and RVN without CPG 10101 in HCV positive subjects who were classified as non-responders to previous adequate PEG-IFN plus RVN therapy.

Study Status: Completed


Condition Intervention Phase
Hepatitis C Drug: CPG 10101
Drug: Pegylated-interferon-alpha 2b
Drug: Ribavirin
Phase 2

Verified by Pfizer May, 2008

Sponsored by: Pfizer
Information provided by: Pfizer identifier: NCT00277238

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site